Novavax, Inc. reported $414M of revenue over the trailing twelve months, −62% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $414M (to Q2 2026). Net income: −$248M, trailing twelve months to Q2 2026. Free cash flow: −$42M, trailing twelve months to Q2 2026. Operating margin: −88%, trailing twelve months to Q2 2026.

NVAXNovavax, Inc.

Healthcare

$9.69+14% 1Y

$9.69

$6.2252 weeks$12.83

NVAX as reported

Novavax, Inc. reported $414M of revenue over the trailing twelve months, −62% on the year before. 10 reported series are charted on this page, each one as filed.

$414M

Revenue, trailing twelve months · to Q2 2026 · −62% against the twelve months before

Net income: −$248M
Net income · −159% year on year · trailing twelve months to Q2 2026
Free cash flow: −$42M
Free cash flow · −93% year on year · trailing twelve months to Q2 2026
Operating margin: −88%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NVAX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$414M	−62%	Q2 2026
Net income	−$248M	−159%	Q2 2026
EPS	−$1.58	−170%	Q2 2026
Gross margin	77%	n/a	Q2 2026
Operating margin	−88%	n/a	Q2 2026
Net margin	−94%	n/a	Q2 2026
ROE	−93%	n/a	Q2 2026
ROA	8.0%	n/a	Q2 2026
ROIC	78%	n/a	Q3 2022 · 15 quarters behind
Free cash flow	−$42M	−93%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.